Stocktwits Biotech Dealmaker: Gilead And Roche Double Down On Early-Stage Assets Over Full Buyouts This Week

Inflammation, cancer therapies called antibody-drug conjugates, and next-generation T-cell engagers with possibilities in treating cancer drew the biggest capital in the relatively slow week for biotech dealmaking.